Pharmacosmos Therapeutics

What Pharmacosmos Therapeutics does

Pharmacosmos Therapeutics Inc. is a US-based specialty pharmaceutical company and wholly-owned subsidiary of the Danish family-owned Pharmacosmos A/S, founded in 1965. The US entity was established in Morristown, New Jersey on September 10, 2019 and focuses on two therapeutic areas: iron deficiency anemia and chemotherapy-induced myelosuppression. The company commercializes two FDA-approved products, Monoferric (ferric derisomaltose), an intravenous iron injection launched in the US in October 2020, and COSELA (trilaciclib), a first-in-class CDK4/6 inhibitor acquired in 2024 through the $405 million take-private of G1 Therapeutics. A third asset, petadeferitrin, is in Phase II trials for transfusion-dependent thalassemia. The technology platform is grounded in proprietary carbohydrate chemistry and cell cycle biology, with cGMP manufacturing based in Holbaek, Denmark dating to 1983.

The business model is a traditional specialty pharmaceutical sales model: direct field sales forces of specialty account representatives target hospitals, oncology practices, specialty clinics, and healthcare providers, with products distributed through specialty pharmacies and pharmaceutical wholesalers. Pricing is managed through standard channels including insurance reimbursement, Medicare Part D, and patient assistance programs, with no public price disclosure. The commercial organization spans 700+ employees across the US, UK/Ireland, Germany, the Nordics, Canada, and China, and products are available in more than 80 countries. Customer segments are fragmented end prescribers and institutional buyers; no single named enterprise customer accounts for material share.

The company is led by a third-generation family CEO (Tobias S. Christensen) and pursues growth through a combination of organic product launches, geographic expansion, and inorganic M&A, as evidenced by the G1 and AbFero acquisitions and the establishment of new subsidiaries in Canada and China. The parent remains family-owned, providing capital flexibility absent from publicly traded peers.

Name

Pharmacosmos Therapeutics

Legal name

Pharmacosmos Therapeutics Inc.

Website

https://pharmacosmos.us

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Pharmacosmos Therapeutics is a US specialty pharmaceutical subsidiary of Danish family-owned Pharmacosmos A/S, commercializing FDA-approved Monoferric for iron deficiency anemia and COSELA for chemotherapy-induced myelosuppression across 80+ countries, with a Phase II iron chelator pipeline.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals - Iron Metabolism and Oncology Supportive Care

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

akta.pro secondary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Iron deficiency anemia treatment
• Intravenous iron therapy
• Chemotherapy-induced myelosuppression
• Specialty pharmaceutical products
• Iron chelation therapy

Headquarters

HQ city

Morristown

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations, Infrastructure

Revenue model

1. Specialty Pharmaceutical Product Sales: Revenue generated from the sale of FDA-approved pharmaceutical products including Monoferric® (ferric derisomaltose) for iron deficiency anemia and COSELA® (trilaciclib) for chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Pharmacosmos Therapeutics develops, manufactures, and commercializes specialty pharmaceutical products for iron metabolism and blood-related disorders. Its approved portfolio includes Monoferric (ferric derisomaltose), an IV iron therapy for iron deficiency anemia, and COSELA (trilaciclib), a first-in-class CDK4/6 inhibitor that reduces chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer patients. The company also operates a clinical pipeline, including the investigational iron chelator petadeferitrin for transfusion-dependent thalassemia.

Product overview

Pharmacosmos Therapeutics is a pharmaceutical company focused on developing and commercializing treatments for iron metabolism disorders and chemotherapy-induced myelosuppression. The company's approved product portfolio includes Monoferric (ferric derisomaltose) for iron deficiency anemia and COSELA (trilaciclib) for chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer. The portfolio was expanded through the 2024 acquisition of G1 Therapeutics. The pipeline includes petadeferitrin, an investigational iron chelator for transfusion-dependent thalassemia. Building on expertise in carbohydrate chemistry and cell cycle biology, the company targets unmet patient needs in blood-related disorders.

Differentiator

Problem solved

Functional benefit

Brands

• Monoferric: Ferric derisomaltose injection - intravenous iron treatment for iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, and who have non-hemodialysis dependent chronic kidney disease
• COSELA
• Petadeferitrin

Products and services

• Monoferric (ferric derisomaltose) FDA-approved intravenous iron injection for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had an unsatisfactory response to oral iron, and for non-hemodialysis dependent chronic kidney disease. Administered as a single infusion. Marketed through healthcare providers, specialty pharmacies, and hospital systems.
• COSELA (trilaciclib) First-in-class CDK4/6 inhibitor administered as an intravenous infusion prior to chemotherapy to reduce the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer. Acquired through the 2024 G1 Therapeutics transaction and commercialized by Pharmacosmos Therapeutics Inc. in the US.
• Petadeferitrin Novel investigational iron chelator under development for the treatment of transfusion-dependent thalassemia and iron overload. Currently in Phase II clinical trials and not yet approved for commercial use.

Quantifiable outcome

• Monoferric® is FDA-approved for iron deficiency anemia in adult patients intolerant to oral iron or with unsatisfactory oral iron response, and for non-hemodialysis dependent chronic kidney disease.
• +1 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• G1 Therapeutics Inc.coreStrategic or Co-development Partner · 18 September 2024Pharmacosmos A/S completed acquisition of G1 Therapeutics Inc. for approximately $405 million through a tender offer and subsequent merger, acquiring a 74.64% stake. The deal allowed Pharmacosmos to take control of G1 and merge it into its U.S. subsidiary, Pharmacosmos Therapeutics Inc., with G1's shares delisted from NASDAQ. This acquisition expanded Pharmacosmos's portfolio to include COSELA® (trilaciclib) for chemotherapy-induced myelosuppression.

Scale indicators5 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• CSL Vifor (Vifor Pharma): Specialty pharmaceutical business focused on iron deficiency and nephrology, with Ferinject/Injectafer (ferric carboxymaltose) the global IV iron market leader. Direct head-to-head competitor to Pharmacosmos' Monoferric in hospital and specialty channels.
• American Regent (Daiichi Sankyo): US specialty injectables subsidiary of Daiichi Sankyo that markets Injectafer (ferric carboxymaltose) and other IV iron products. The principal US-based rival to Monoferric in the IV iron category.
• Fresenius Kabi: Global specialty/generic injectable and IV iron manufacturer competing in the same hospital and clinic channels as Monoferric, with comparable cGMP manufacturing scale and global distribution.
• Swedish Orphan Biovitrum (Sobi): Specialty pharma focused on rare diseases and hematology, including iron-related and blood disorders. Overlapping therapeutic areas with Pharmacosmos' hematology/iron metabolism franchise and similar specialty commercial model.

Broad incumbents

• Recordati: European specialty pharma with established presence in rare diseases and specialty primary care, similar in size and commercial orientation to Pharmacosmos. Comparable as a privately-influenced specialty pharma building global franchises.
• Chiesi Farmaceutici: Family-owned global specialty pharma with rare disease, hematology, and specialty hospital portfolios. Comparable in ownership structure (family-controlled) and specialty commercial orientation, including prior employer of Pharmacosmos Therapeutics' President.
• Bristol Myers Squibb: Major oncology innovator with leading SCLC and ES-SCLC immunotherapy regimens (e.g., Opdivo + chemotherapy) that define the treatment landscape into which COSELA is administered. Indirect but powerful peer through the underlying ES-SCLC market.
• Pfizer: Global pharma with broad hematology, oncology, and rare disease franchises. Comparable as a competitor for medical affairs and commercial talent, and as a potential strategic acquirer of differentiated specialty assets like COSELA.
• Teva Pharmaceutical Industries: Large specialty and generics pharma with significant US specialty hospital presence. Comparable as a US specialty commercial competitor and as a prior employer of Pharmacosmos Therapeutics' US General Counsel.

Regional players

• H. Lundbeck: Danish specialty pharma with a CNS focus but a long-standing relationship with Pharmacosmos' Christensen family (Lars Christensen previously worked at Lundbeck). Comparable as a Danish-headquartered, founder-influenced specialty pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmacosmos Therapeutics